Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting

Jenna E Yousif; Joseph F Merola; Lourdes M Perez-Chada; Caterina Zagona-Prizio; April W Armstrong; Alexis Ogdie; Sangyoon Shin; Alice B Gottlieb

doi:10.3899/jrheum.211328

Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting

J Rheumatol. 2022 Jun;49(6 Suppl 1):40-43. doi: 10.3899/jrheum.211328. Epub 2022 Apr 1.

Authors

Jenna E Yousif¹, Joseph F Merola², Lourdes M Perez-Chada³, Caterina Zagona-Prizio⁴, April W Armstrong⁴, Alexis Ogdie⁵, Sangyoon Shin⁶, Alice B Gottlieb¹

Affiliations

¹ J.E. Yousif, A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sin ai, New York, New York.
² J.F. Merola, MD, MMSc, Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts; jfmerola@bwh.harvard.edu.
³ L.M. Perez-Chada, MD, MMSc, Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ C. Zagona-Prizio, BS, A.W. Armstrong, MD, MPH, Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
⁵ A. Ogdie, MD, MSCE, Department of Medicine/Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
⁶ S. Shin, DO, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

PMID: 35365577
DOI: 10.3899/jrheum.211328

Abstract

The International Dermatology Outcome Measures (IDEOM) initiative presented an update on their progress related to instruments for psoriasis (PsO) and psoriatic arthritis (PsA) patient-centered outcome measures at the 2021 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Treatment Satisfaction working group presented the development of a 7-item treatment satisfaction questionnaire specific for dermatological conditions. The group is beginning by assessing the validity and reliability of the instrument in PsO patient populations, with the ultimate goal of validating it for use in multiple dermatological diseases. The Musculoskeletal Symptoms working group discussed how implementation of a screening measurement tool in patients with PsO can help identify unknown diagnoses of PsA or prevent worsening of symptoms.

Keywords: GRAPPA; outcome assessment; psoriasis; psoriatic arthritis.

MeSH terms

Arthritis, Psoriatic* / diagnosis
Arthritis, Psoriatic* / therapy
Dermatology*
Humans
Psoriasis* / diagnosis
Psoriasis* / therapy
Reproducibility of Results
Rheumatology*
Skin